Professional Media briefs: December 2013

Professional Media briefs: December 2013
Professional Media briefs: December 2013

Modern Healthcare wrapped the first phase of an allover redesign. The new print publication rolled out at the end of October with a new logo, bolder graphics and new content sections. ­Editor Merrill Goozner tells MM&M that readers asked for such usable information as best practices, as well as stories that show the impact these recommendations have. A new website is set to go live in the first half of next year.

Harvard Law, Duke and Stanford Universities have launched the open-access publication Journal of Law and Biosciences, published by Oxford University Press. The co-editors-in-chief include reps from all three schools, supported by an editorial board with experience in disciplines including bioethics, philosophy, neuroscience and psychology.

Patrick Wen is replacing Alfred Yung as Editor-in-Chief of Neuro-Oncology as of January. Wen, a neurology professor at Harvard Medical School chairs the American Academy of Neurology's neuro-oncology division, and is pursuing research that centers on novel treatments for brain ­tumors. Outgoing EIC Yung headed up the publication for seven years, increasing the annual publication schedule from four to 12 issues.


You must be a registered member of MMM to post a comment.

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.